4TEEN4 Pharmaceuticals

Phase 2/3

Hennigsdorf, GermanyFounded 20144teen4.de

4TEEN4 Pharmaceuticals is a clinical-stage biotech company pioneering a novel, pathophysiology-driven approach to treating shock, a critical condition with mortality rates exceeding 40% and no adequate causal therapy. Built on the groundbreaking discovery of circulating Dipeptidyl Peptidase 3 (cDPP3) as a key driver and biomarker, the company is developing invobenitug (procizumab) to neutralize cDPP3 and restore cardiovascular stability. With an experienced leadership team and a biomarker-enriched clinical strategy, 4TEEN4 aims to significantly improve survival for critically ill patients in the ICU.

Founded

2014

Focus

AntibodiesBiologicsDiagnostics

AI Company Overview

Technology Platform

A biomarker-driven therapeutic platform targeting circulating Dipeptidyl Peptidase 3 (cDPP3), a key driver of mortality in shock. The platform combines a neutralizing monoclonal antibody with a companion diagnostic biomarker to identify high-risk patients.

Opportunities

The primary opportunity is addressing the vast unmet need in cardiogenic shock, a lethal condition with no causal therapy.

Success here could enable rapid expansion into other shock etiologies (sepsis, burns, trauma), representing a much larger critical care market.

The biomarker-driven approach also creates opportunities for companion diagnostic partnerships and premium pricing.

Risk Factors

Key risks include the high clinical development hurdle of showing a mortality benefit in a complex, critically ill population, the challenge of driving adoption of a new biomarker (cDPP3) in hospital ICUs, and the commercialization risk of introducing a high-cost biologic for an acute, short-term condition in a cost-conscious hospital setting.

Competitive Landscape

4TEEN4 faces limited direct competition, as the current standard of care for shock is purely supportive (vasopressors, inotropes, mechanical support). Its main competitors are other novel agents in early development for critical care. 4TEEN4 differentiates itself through its first-in-class target (cDPP3), a strong biomarker strategy for patient selection, and an experienced team with a proven track record in translating critical care biomarkers into clinical utility.